Statement: The only cases of cardiac problems in the primary trial occurred in cohort 1.
Primary_evidence: Adverse Events 1:   Total: 67/240 (27.92%)   Anaemia 0/240 (0.00%)   Febrile neutropenia 1/240 (0.42%)   Leukopenia 2/240 (0.83%)   Neutropenia 1/240 (0.42%)   Thrombocytopenia 0/240 (0.00%)   Atrial fibrillation 0/240 (0.00%)   Cardiac failure congestive 2/240 (0.83%)   Cardiac tamponade 1/240 (0.42%)   Cardio-respiratory arrest 1/240 (0.42%)   Left ventricular dysfunction 0/240 (0.00%) Adverse Events 2:   Total: 56/234 (23.93%)   Anaemia 1/234 (0.43%)   Febrile neutropenia 0/234 (0.00%)   Leukopenia 0/234 (0.00%)   Neutropenia 0/234 (0.00%)   Thrombocytopenia 1/234 (0.43%)   Atrial fibrillation 1/234 (0.43%)   Cardiac failure congestive 0/234 (0.00%)   Cardiac tamponade 0/234 (0.00%)   Cardio-respiratory arrest 0/234 (0.00%)   Left ventricular dysfunction 1/234 (0.43%)